Early each year, the United States Senate crafts an annual Department of Defense (DoD) appropriations bill, which includes a list of conditions that are deemed “eligible for study” through the Peer-Reviewed Medical Research Program (PRMRP).
In recent years, the PRMRP funded nearly $10 million in meritorious and meaningful scleroderma research projects. Research on the underlying mechanisms of scleroderma is showing relevance to all fibrosis, which occurs at higher rates among individuals who serve in the military and our veterans. The Senate included “scleroderma” as a condition eligible for study during the current year, FY 2017, and it is important that we thank key Senators on behalf of the community and ask for their support again for FY 2018.
Senators are currently working on the FY 2018 DoD appropriations bill and deciding which conditions will be included on the next PRMRP eligible conditions list. At this critical juncture, please reach out to the offices of your Senators and ask that they “support the inclusion of scleroderma in the DoD PRMRP’s eligible conditions list in FY 2018.”
The mother of a juvenile scleroderma patient herself, Diane Weber started an online Facebook community for Sclero-Moms in a similar circumstance across the country to share ideas and know they are not alone. The page has moms from coast to coast and is by invitation only. To join the conversation and idea exchange, please send an email to Kerri Connolly at firstname.lastname@example.org
PHA Webinar to be held March 23
Join PHA for the first webinar of the newly-diagnosed
series, “Tests, Tests and More Tests: What is PH Diagnostic Testing Telling my
Doctors?” We will review many of the clinical tests that are used in the
diagnosis of PH. The session will discuss the risks and benefits of each test
as well as how the information derived from testing is used to unravel
different diagnoses of pulmonary hypertension. Register Today >>
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
The Scleroderma Foundation is a qualified national nonprofit operating under 501(c)(3) status. The foundation’s federal tax identification number is 52-1375827. Our primary goal is to raise funds for our three-fold mission of support, education and research. The foundation has 20 active chapters and 160 support groups across the country.